vs
Side-by-side financial comparison of HALOZYME THERAPEUTICS, INC. (HALO) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
HALOZYME THERAPEUTICS, INC. is the larger business by last-quarter revenue ($451.8M vs $334.0M, roughly 1.4× WYNDHAM HOTELS & RESORTS, INC.). WYNDHAM HOTELS & RESORTS, INC. runs the higher net margin — -18.0% vs -31.3%, a 13.4% gap on every dollar of revenue. On growth, HALOZYME THERAPEUTICS, INC. posted the faster year-over-year revenue change (51.6% vs -76.3%). HALOZYME THERAPEUTICS, INC. produced more free cash flow last quarter ($217.6M vs $168.0M). Over the past eight quarters, HALOZYME THERAPEUTICS, INC.'s revenue compounded faster (51.9% CAGR vs -4.6%).
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
HALO vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $451.8M | $334.0M |
| Net Profit | $-141.6M | $-60.0M |
| Gross Margin | 82.6% | — |
| Operating Margin | -20.6% | — |
| Net Margin | -31.3% | -18.0% |
| Revenue YoY | 51.6% | -76.3% |
| Net Profit YoY | -203.3% | -170.6% |
| EPS (diluted) | $-1.13 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $451.8M | $334.0M | ||
| Q3 25 | $354.3M | $382.0M | ||
| Q2 25 | $325.7M | $397.0M | ||
| Q1 25 | $264.9M | $316.0M | ||
| Q4 24 | $298.0M | $336.0M | ||
| Q3 24 | $290.1M | $396.0M | ||
| Q2 24 | $231.4M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $-141.6M | $-60.0M | ||
| Q3 25 | $175.2M | $105.0M | ||
| Q2 25 | $165.2M | $87.0M | ||
| Q1 25 | $118.1M | $61.0M | ||
| Q4 24 | $137.0M | $85.0M | ||
| Q3 24 | $137.0M | $102.0M | ||
| Q2 24 | $93.2M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 82.6% | — | ||
| Q3 25 | 84.4% | — | ||
| Q2 25 | 85.8% | — | ||
| Q1 25 | 81.7% | — | ||
| Q4 24 | 85.9% | — | ||
| Q3 24 | 83.0% | — | ||
| Q2 24 | 82.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | -20.6% | -11.4% | ||
| Q3 25 | 61.5% | 46.6% | ||
| Q2 25 | 62.2% | 37.8% | ||
| Q1 25 | 53.4% | 35.4% | ||
| Q4 24 | 58.9% | 38.4% | ||
| Q3 24 | 56.3% | 43.2% | ||
| Q2 24 | 50.7% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | -31.3% | -18.0% | ||
| Q3 25 | 49.5% | 27.5% | ||
| Q2 25 | 50.7% | 21.9% | ||
| Q1 25 | 44.6% | 19.3% | ||
| Q4 24 | 46.0% | 25.3% | ||
| Q3 24 | 47.2% | 25.8% | ||
| Q2 24 | 40.3% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $-1.13 | $-0.77 | ||
| Q3 25 | $1.43 | $1.36 | ||
| Q2 25 | $1.33 | $1.13 | ||
| Q1 25 | $0.93 | $0.78 | ||
| Q4 24 | $1.06 | $1.06 | ||
| Q3 24 | $1.05 | $1.29 | ||
| Q2 24 | $0.72 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $133.8M | $64.0M |
| Total DebtLower is stronger | $2.1B | — |
| Stockholders' EquityBook value | $48.8M | $468.0M |
| Total Assets | $2.5B | $4.2B |
| Debt / EquityLower = less leverage | 43.89× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $133.8M | $64.0M | ||
| Q3 25 | $419.7M | $70.0M | ||
| Q2 25 | $61.9M | $50.0M | ||
| Q1 25 | $176.3M | $48.0M | ||
| Q4 24 | $115.8M | $103.0M | ||
| Q3 24 | $154.3M | $72.0M | ||
| Q2 24 | $187.9M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $2.1B | $2.5B | ||
| Q3 25 | $1.5B | $2.6B | ||
| Q2 25 | $1.5B | $2.5B | ||
| Q1 25 | $1.5B | $2.5B | ||
| Q4 24 | $1.5B | $2.4B | ||
| Q3 24 | $1.5B | $2.4B | ||
| Q2 24 | $1.5B | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $48.8M | $468.0M | ||
| Q3 25 | $503.9M | $583.0M | ||
| Q2 25 | $332.7M | $570.0M | ||
| Q1 25 | $482.3M | $579.0M | ||
| Q4 24 | $363.8M | $650.0M | ||
| Q3 24 | $452.7M | $583.0M | ||
| Q2 24 | $289.4M | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $2.5B | $4.2B | ||
| Q3 25 | $2.2B | $4.3B | ||
| Q2 25 | $2.1B | $4.3B | ||
| Q1 25 | $2.2B | $4.2B | ||
| Q4 24 | $2.1B | $4.2B | ||
| Q3 24 | $2.1B | $4.2B | ||
| Q2 24 | $2.0B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 43.89× | 5.37× | ||
| Q3 25 | 3.00× | 4.43× | ||
| Q2 25 | 4.54× | 4.44× | ||
| Q1 25 | 3.13× | 4.29× | ||
| Q4 24 | 4.14× | 3.72× | ||
| Q3 24 | 3.32× | 4.19× | ||
| Q2 24 | 5.19× | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $219.0M | $367.0M |
| Free Cash FlowOCF − Capex | $217.6M | $168.0M |
| FCF MarginFCF / Revenue | 48.2% | 50.3% |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $644.6M | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $219.0M | $152.0M | ||
| Q3 25 | $178.6M | $86.0M | ||
| Q2 25 | $99.7M | $70.0M | ||
| Q1 25 | $154.2M | $59.0M | ||
| Q4 24 | $178.5M | $134.0M | ||
| Q3 24 | $115.4M | $79.0M | ||
| Q2 24 | $55.8M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | $217.6M | $136.0M | ||
| Q3 25 | $175.6M | $75.0M | ||
| Q2 25 | $98.1M | $58.0M | ||
| Q1 25 | $153.3M | $52.0M | ||
| Q4 24 | $175.4M | $109.0M | ||
| Q3 24 | $113.9M | $71.0M | ||
| Q2 24 | $53.2M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | 48.2% | 40.7% | ||
| Q3 25 | 49.6% | 19.6% | ||
| Q2 25 | 30.1% | 14.6% | ||
| Q1 25 | 57.9% | 16.5% | ||
| Q4 24 | 58.9% | 32.4% | ||
| Q3 24 | 39.3% | 17.9% | ||
| Q2 24 | 23.0% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 4.8% | ||
| Q3 25 | 0.9% | 2.9% | ||
| Q2 25 | 0.5% | 3.0% | ||
| Q1 25 | 0.4% | 2.2% | ||
| Q4 24 | 1.0% | 7.4% | ||
| Q3 24 | 0.5% | 2.0% | ||
| Q2 24 | 1.1% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.02× | 0.82× | ||
| Q2 25 | 0.60× | 0.80× | ||
| Q1 25 | 1.31× | 0.97× | ||
| Q4 24 | 1.30× | 1.58× | ||
| Q3 24 | 0.84× | 0.77× | ||
| Q2 24 | 0.60× | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
